All GLG News Analyses Filed Under: Ophthalmology

Bifocal LASIK surgery is the current Holy Grail of refractive surgeons.  This article mentions a new technique that may result in a useful monofocal technique, although it is not well described.

The FDA has just approved a "bifocal LASIK" technique from Advanced Medical Optics using their CustomVue Excimer laser platform.   It has been approved as " a new device". In actuality, it is neither a new device nor does it provide bifocal vision.

The FDA recently approved a CustomVue Monovision LASIK surgery (AMO; EYE) for the treatment of presbyopia. The premise is to treat one eye for distance and allow the other (partially treated) for near vision reducing the need for spectacles.  This is nothing new and has been used for years as ...

This article is suggesting that it is a new procedure to allow a bifocal correction during lasik.  The Bifocal Lasik undercorrects nearsightedness in one eye, essentially monovision.  Monovision Lasik has been used for years to allow patients the ability to see distance and near without glasses,...

AMO (EYE) recently outbid a private equity firm to acquire Bausch & Lomb (BOL).  It has the potential to add to AMO's market share and establish it as the force in Ophthalmology.

Currently the ophthalmic device market is organized into an oligopoly including Alcon, AMO and Bausch.  AMO has shown fairly dramatic growth with its acquisition of VISX, Intralase and Wavefront Sciences.  However, AMO's potential acquisition of Bausch is on a grander scale.  There are...

In this news release presented today, this leading ophthalmic journal reports that AMO has presented the highest bid for the purchase of Bausch and Lomb.  

- I wouldn't count Warburg Pincus out of the running just yet... they have very deep pockets.  Other bidders may enter the fray as well. - AMO aims to fill in gaps in its businesses, from both an operations perspective (e.g. eyeglasses and contact lenses) and geography (B&L has a strong...

Dr Smiddy reviewed age-related macular degeneration studies to evaluate the cost for the visual benefit of various treatment approaches, and then compared them with the costs for treating other retinal conditions. This study founds costs for treating wet macular degeneation could be as high as $9000...

In a study of patients with choroidal neovascularization due to age-related macular degeneration, Lazic and Gabric demonstrated that improvements in vision and reduction of central macular thickness after one month and their maintenance over three months are more significant after verteporfin photodynamic...